75 results on '"Mavigner M"'
Search Results
2. OP 3.4 – 00197 Infected naïve CD4+ T cells in children with HIV can proliferate and persist on ART
- Author
-
Katusiime, M., primary, Guo, S., additional, Neer, V., additional, Patro, S., additional, Wu, X., additional, Horner, A., additional, Chahroudi, A., additional, Mavigner, M., additional, and Kearney, M., additional
- Published
- 2022
- Full Text
- View/download PDF
3. Rapid progression is associated with lymphoid follicle dysfunction in SIV-infected infant rhesus macaques
- Author
-
Wood, M, Jones, C, Lippy, A, Oliver, B, Walund, B, Fancher, K, Fisher, B, Wright, P, Fuller, J, Murapa, P, Habib, J, Mavigner, M, Chahroudi, A, Sather, N, Fuller, D, Sodora, D, Wood, M, Jones, C, Lippy, A, Oliver, B, Walund, B, Fancher, K, Fisher, B, Wright, P, Fuller, J, Murapa, P, Habib, J, Mavigner, M, Chahroudi, A, Sather, N, Fuller, D, and Sodora, D
- Published
- 2021
4. Rapid progression is associated with lymphoid follicle dysfunction in SIV-infected infant rhesus macaques.
- Author
-
Wood, MP, Jones, CI, Lippy, A, Oliver, BG, Walund, B, Fancher, KA, Fisher, BS, Wright, PJ, Fuller, JT, Murapa, P, Habib, J, Mavigner, M, Chahroudi, A, Sather, DN, Fuller, DH, Sodora, DL, Wood, MP, Jones, CI, Lippy, A, Oliver, BG, Walund, B, Fancher, KA, Fisher, BS, Wright, PJ, Fuller, JT, Murapa, P, Habib, J, Mavigner, M, Chahroudi, A, Sather, DN, Fuller, DH, and Sodora, DL
- Abstract
HIV-infected infants are at an increased risk of progressing rapidly to AIDS in the first weeks of life. Here, we evaluated immunological and virological parameters in 25 SIV-infected infant rhesus macaques to understand the factors influencing a rapid disease outcome. Infant macaques were infected with SIVmac251 and monitored for 10 to 17 weeks post-infection. SIV-infected infants were divided into either typical (TypP) or rapid (RP) progressor groups based on levels of plasma anti-SIV antibody and viral load, with RP infants having low SIV-specific antibodies and high viral loads. Following SIV infection, 11 out of 25 infant macaques exhibited an RP phenotype. Interestingly, TypP had lower levels of total CD4 T cells, similar reductions in CD4/CD8 ratios and elevated activation of CD8 T cells, as measured by the levels of HLA-DR, compared to RP. Differences between the two groups were identified in other immune cell populations, including a failure to expand activated memory (CD21-CD27+) B cells in peripheral blood in RP infant macaques, as well as reduced levels of germinal center (GC) B cells and T follicular helper (Tfh) cells in spleens (4- and 10-weeks post-SIV). Reduced B cell proliferation in splenic germinal GCs was associated with increased SIV+ cell density and follicular type 1 interferon (IFN)-induced immune activation. Further analyses determined that at 2-weeks post SIV infection TypP infants exhibited elevated levels of the GC-inducing chemokine CXCL13 in plasma, as well as significantly lower levels of viral envelope diversity compared to RP infants. Our findings provide evidence that early viral and immunologic events following SIV infection contributes to impairment of B cells, Tfh cells and germinal center formation, ultimately impeding the development of SIV-specific antibody responses in rapidly progressing infant macaques.
- Published
- 2021
5. Pharmacological Modulation of the Wnt/β-Catenin Pathway Inhibits Proliferation and Promotes Differentiation of Long-Lived Memory CD4 + T Cells in Antiretroviral Therapy-Suppressed Simian Immunodeficiency Virus-Infected Macaques
- Author
-
Mavigner, M., primary, Zanoni, M., additional, Tharp, G. K., additional, Habib, J., additional, Mattingly, C. R., additional, Lichterfeld, M., additional, Nega, M. T., additional, Vanderford, T. H., additional, Bosinger, S. E., additional, and Chahroudi, A., additional
- Published
- 2019
- Full Text
- View/download PDF
6. The latency reversal activity of the SMAC mimetic AZD5582 in ART-suppressed SIV-infected rhesus macaques is potentiated by CD8a cell depletion
- Author
-
Mavigner, M., primary, Brooks, A., additional, Mattingly, C., additional, Vanderford, T., additional, Keele, B., additional, Lifson, J., additional, Dunham, R., additional, Margolis, D., additional, Silvestri, G., additional, and Chahroudi, A., additional
- Published
- 2019
- Full Text
- View/download PDF
7. CD8 depletion plus signaling of the non-canonical NF-kB pathway reverses latency in SIV-infected, ART-suppressed rhesus macaques
- Author
-
Mavigner, M., primary, Brooks, A.D., additional, Tharp, G.K., additional, Mattingly, C., additional, Schoof, N., additional, Vanderford, T.H., additional, Bosinger, S.E., additional, Sampey, G.C., additional, Galardi, C., additional, Dunham, R.M., additional, Margolis, D.M., additional, Silvestri, G., additional, and Chahroudi, A., additional
- Published
- 2019
- Full Text
- View/download PDF
8. Sting agonist as a kick and kill agent to target the HIV reservoir
- Author
-
Mavigner, M., primary, Brooks, A.D., additional, Koblansky, A., additional, Galardi, C., additional, Madsen, H., additional, Margolis, D.M., additional, Silvestri, G., additional, and Chahroudi, A., additional
- Published
- 2019
- Full Text
- View/download PDF
9. Increased CXCR3+ T Cells Impairs Recruitment of T-Helper Type 17 Cells via Interferon γ and Interleukin 18 in the Small Intestine Mucosa During Treated HIV-1 Infection
- Author
-
Loiseau, C, primary, Requena, M, additional, Nayrac, M, additional, Mavigner, M, additional, Cazabat, M, additional, Iscache, A L, additional, Carrere, N, additional, Suc, B, additional, Alric, L, additional, Izopet, J, additional, and Delobel, P, additional
- Published
- 2019
- Full Text
- View/download PDF
10. Pharmacological Modulation of the Wnt/β-Catenin Pathway Inhibits Proliferation and Promotes Differentiation of Long- Lived Memory CD4+ T Cells in Antiretroviral Therapy- Suppressed Simian Immunodeficiency Virus-Infected Macaques.
- Author
-
Mavigner, M., Zanoni, M., Tharp, G. K., Habib, J., Mattingly, C. R., Lichterfeld, M., Nega, M. T., Vanderford, T. H., Bosinger, S. E., and Chahroudi, A.
- Subjects
- *
T cells , *MACAQUES , *RHESUS monkeys , *STEM cells , *IMMUNODEFICIENCY - Abstract
The major obstacle to human immunodeficiency type 1 virus (HIV-1) eradication is a reservoir of latently infected cells that persists despite long-term antiretroviral therapy (ART) and is maintained through cellular proliferation. Long-lived memory CD4+ T cells with high self-renewal capacity, such as central memory (CM) T cells and stem cell memory (SCM) T cells, are major contributors to the viral reservoir in HIV-infected individuals on ART. The Wnt/β-catenin signaling pathway regulates the balance between self-renewal and differentiation of SCM and CM T cells, and pharmacological manipulation of this pathway offers an opportunity to interfere with the proliferation of latently infected cells. Here, we evaluated in vivo a novel approach to inhibit self-renewal of SCM and CM CD4+ T cells in the rhesus macaque (RM) model of simian immunodeficiency (SIV) infection. We used an inhibitor of the Wnt/β-catenin pathway, PRI-724, that blocks the interaction between the coactivator CREB-binding protein (CBP) and β-catenin, resulting in the cell fate decision to differentiate rather than proliferate. Our study shows that PRI-724 treatment of ARTsuppressed SIVmac251-infected RMs resulted in decreased proliferation of SCM and CM T cells and modified the SCM and CM CD4+ T cell transcriptome toward a profile of more differentiated memory T cells. However, short-term treatment with PRI- 724 alone did not significantly reduce the size of the viral reservoir. This work demonstrates for the first time that stemness pathways of long-lived memory CD4= T cells can be pharmacologically modulated in vivo, thus establishing a novel strategy to target HIV persistence. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
11. CCR6− regulatory T cells blunt the restoration of gut Th17 cells along the CCR6–CCL20 axis in treated HIV-1-infected individuals
- Author
-
Loiseau, C., primary, Requena, M., additional, Mavigner, M., additional, Cazabat, M., additional, Carrere, N., additional, Suc, B., additional, Barange, K., additional, Alric, L., additional, Marchou, B., additional, Massip, P., additional, Izopet, J., additional, and Delobel, P., additional
- Published
- 2016
- Full Text
- View/download PDF
12. OA4-5 LB SIV persistence in ART-treated infant rhesus macaques
- Author
-
Mavigner, M., primary, Deleage, C., additional, Habib, J., additional, Rosen, E., additional, Kashuba, A., additional, Amblard, F., additional, Schinazi, R., additional, Geleziunas, R., additional, Hesselgesser, J., additional, Li, B., additional, Hattersley, J., additional, McGary, C., additional, Paiardini, M., additional, Wood, M., additional, Sodora, D., additional, Silvestri, G., additional, Estes, J., additional, and Chahroudi, A., additional
- Published
- 2016
- Full Text
- View/download PDF
13. CCR6− regulatory T cells blunt the restoration of gut Th17 cells along the CCR6-CCL20 axis in treated HIV-1-infected individuals.
- Author
-
Loiseau, C, Requena, M, Mavigner, M, Cazabat, M, Carrere, N, Suc, B, Barange, K, Alric, L, Marchou, B, Massip, P, Izopet, J, and Delobel, P
- Published
- 2016
- Full Text
- View/download PDF
14. CCR6−regulatory T cells blunt the restoration of gut Th17 cells along the CCR6–CCL20 axis in treated HIV-1-infected individuals
- Author
-
Loiseau, C, Requena, M, Mavigner, M, Cazabat, M, Carrere, N, Suc, B, Barange, K, Alric, L, Marchou, B, Massip, P, Izopet, J, and Delobel, P
- Abstract
The gut CD4+T cells, particularly the T helper type 17 (Th17) subset, are not completely restored in most HIV-1-infected individuals despite combined antiretroviral therapy, when initiated at the chronic phase of infection. We show here that the CCR6–CCL20 chemotactic axis is altered, with reduced CCL20 production by small intestine epithelial cells in treated HIV-1-infected individuals. This leads to impaired CCR6+CD4+T-cell homing, particularly Th17 cells, to the small intestine mucosa. In contrast, the frequency of gut FoxP3+T regulatory (Treg) cells, specifically the CCR6−subset, was increased. The resulting imbalance in the Th17/CCR6−Treg ratio and the associated shift from interleukin (IL)-17 to IL-10 and transforming growth factor-β (TGF-β) blunts CCL20 production by enterocytes, perpetuating a negative feedback for the recruitment of CCR6+CD4+T cells to the small intestine in treated HIV-1-infected individuals.
- Published
- 2016
- Full Text
- View/download PDF
15. Altered CD4+ T cell homing to the gut impairs mucosal immune reconstitution in treated HIV-infected individuals.
- Author
-
Mavigner M, Cazabat M, Dubois M, L'Faqihi FE, Requena M, Pasquier C, Klopp P, Amar J, Alric L, Barange K, Vinel JP, Marchou B, Massip P, Izopet J, Delobel P, Mavigner, Maud, Cazabat, Michelle, Dubois, Martine, L'Faqihi, Fatima-Ezzahra, and Requena, Mary
- Abstract
Depletion of CD4+ T cells from the gut occurs rapidly during acute HIV-1 infection. This has been linked to systemic inflammation and disease progression as a result of translocation of microbial products from the gut lumen into the bloodstream. Combined antiretroviral therapy (cART) substantially restores CD4+ T cell numbers in peripheral blood, but the gut compartment remains largely depleted of such cells for poorly understood reasons. Here, we show that a lack of recruitment of CD4+ T cells to the gut could be involved in the incomplete mucosal immune reconstitution of cART-treated HIV-infected individuals. We investigated the trafficking of CD4+ T cells expressing the gut-homing receptors CCR9 and integrin α4β7 and found that many of these T cells remained in the circulation rather than repopulating the mucosa of the small intestine. This is likely because expression of the CCR9 ligand CCL25 was lower in the small intestine of HIV-infected individuals. The defective gut homing of CCR9+β7+ CD4+ T cells - a population that we found included most gut-homing Th17 cells, which have a critical role in mucosal immune defense - correlated with high plasma concentrations of markers of mucosal damage, microbial translocation, and systemic T cell activation. Our results thus describe alterations in CD4+ T cell homing to the gut that could prevent efficient mucosal immune reconstitution in HIV-infected individuals despite effective cART. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
16. Long-term alterations in brain and behavior after postnatal Zika virus infection in infant macaques
- Author
-
Chahroudi, A., Jean, S.M., Raper, J., Fair, D., Alvarado, M.C., Earl, E., Styner, M., Kovacs-Balint, Z., Mattingly, C., Mavigner, M., Habib, J., Feczko, E., Burke, M.W., Sanchez, M.M., Gumber, S., Cohen, J.K., and Suthar, M.S.
- Subjects
3. Good health - Abstract
Zika virus (ZIKV) infection has a profound impact on the fetal nervous system. The postnatal period is also a time of rapid brain growth, and it is important to understand the potential neurobehavioral consequences of ZIKV infection during infancy. Here we show that postnatal ZIKV infection in a rhesus macaque model resulted in long-term behavioral, motor, and cognitive changes, including increased emotional reactivity, decreased social contact, loss of balance, and deficits in visual recognition memory at one year of age. Structural and functional MRI showed that ZIKV-infected infant rhesus macaques had persistent enlargement of lateral ventricles, smaller volumes and altered functional connectivity between brain areas important for socioemotional behavior, cognitive, and motor function (e.g. amygdala, hippocampus, cerebellum). Neuropathological changes corresponded with neuroimaging results and were consistent with the behavioral and memory deficits. Overall, this study demonstrates that postnatal ZIKV infection in this model may have long-lasting neurodevelopmental consequences.
17. AZD5582 plus SIV-specific antibodies reduce lymph node viral reservoirs in antiretroviral therapy-suppressed macaques.
- Author
-
Dashti A, Sukkestad S, Horner AM, Neja M, Siddiqi Z, Waller C, Goldy J, Monroe D, Lin A, Schoof N, Singh V, Mavigner M, Lifson JD, Deleage C, Tuyishime M, Falcinelli SD, King HAD, Ke R, Mason RD, Archin NM, Dunham RM, Safrit JT, Jean S, Perelson AS, Margolis DM, Ferrari G, Roederer M, Silvestri G, and Chahroudi A
- Subjects
- Animals, Macaca mulatta, Anti-Retroviral Agents pharmacology, Anti-Retroviral Agents therapeutic use, Virus Latency, Virus Replication, Antibodies therapeutic use, Lymph Nodes, CD4-Positive T-Lymphocytes, Viral Load, HIV Infections, Simian Acquired Immunodeficiency Syndrome, Simian Immunodeficiency Virus physiology, HIV-1
- Abstract
The main barrier to HIV cure is a persistent reservoir of latently infected CD4
+ T cells harboring replication-competent provirus that fuels rebound viremia upon antiretroviral therapy (ART) interruption. A leading approach to target this reservoir involves agents that reactivate latent HIV proviruses followed by direct clearance of cells expressing induced viral antigens by immune effector cells and immunotherapeutics. We previously showed that AZD5582, an antagonist of inhibitor of apoptosis proteins and mimetic of the second mitochondrial-derived activator of caspases (IAPi/SMACm), induces systemic reversal of HIV/SIV latency but with no reduction in size of the viral reservoir. In this study, we investigated the effects of AZD5582 in combination with four SIV Env-specific Rhesus monoclonal antibodies (RhmAbs) ± N-803 (an IL-15 superagonist) in SIV-infected, ART-suppressed rhesus macaques. Here we confirm the efficacy of AZD5582 in inducing SIV reactivation, demonstrate enhancement of latency reversal when AZD5582 is used in combination with N-803 and show a reduction in total and replication-competent SIV-DNA in lymph-node-derived CD4+ T cells in macaques treated with AZD5582 + RhmAbs. Further exploration of this therapeutic approach may contribute to the goal of achieving an HIV cure., (© 2023. The Author(s).)- Published
- 2023
- Full Text
- View/download PDF
18. Treatment with sofosbuvir attenuates the adverse neurodevelopmental consequences of Zika virus infection in infant rhesus macaques.
- Author
-
Medina A, Rusnak R, Richardson R, Zimmerman MG, Suthar M, Schoof N, Kovacs-Balint Z, Mavigner M, Sanchez M, Chahroudi A, and Raper J
- Subjects
- Animals, Macaca mulatta, Sofosbuvir therapeutic use, Antiviral Agents therapeutic use, Zika Virus Infection complications, Zika Virus Infection drug therapy, Zika Virus
- Abstract
Zika virus (ZIKV) infection during infancy in a rhesus macaque (RM) model negatively impacts brain development resulting in long-term behavioral alterations. The current study investigated whether postexposure prophylaxis could alleviate these negative neurodevelopmental consequences. Three RM infants received a 14-day course of sofosbuvir (SOF; 15 mg/kg p.o.) treatment starting at 3 days post-infection with a Puerto Rican strain of ZIKV (PRVABC59) and were then monitored longitudinally for one year. In contrast to ZIKV-infected infant RMs who did not receive SOF, postexposure SOF treatment mitigated the neurodevelopmental, behavioral and cognitive changes seen after postnatal ZIKV infection even while not accelerating viral clearance from the blood. These data suggest that antiviral treatment may help ameliorate some, but not all, of the neurodevelopmental abnormalities associated with early postnatal ZIKV infection., Competing Interests: Declaration of Competing Interest None., (Copyright © 2023 Elsevier B.V. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
19. Broadly neutralizing antibodies: "The next thing" to treat children with HIV?
- Author
-
Mavigner M and Chahroudi A
- Subjects
- Child, Humans, Antibodies, Neutralizing immunology, Antibodies, Neutralizing therapeutic use, HIV Antibodies therapeutic use, Broadly Neutralizing Antibodies immunology, Broadly Neutralizing Antibodies therapeutic use, HIV Infections drug therapy, HIV Infections immunology, HIV-1
- Abstract
Monthly treatment with two neutralizing antibodies maintained HIV suppression in almost half of children who received early antiretroviral treatment (Shapiro et al .).
- Published
- 2023
- Full Text
- View/download PDF
20. Investigation of Blood Plasma Viral Nucleocapsid Antigen as a Marker of Active Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant Infection.
- Author
-
Damhorst GL, Schoof N, Nguyen PV, Verkerke H, Wilber E, McLendon K, O'Sick W, Baugh T, Cheedarla S, Cheedarla N, Stittleburg V, Fitts EC, Neja MA, Babiker A, Piantadosi A, Roback JD, Waggoner JJ, Mavigner M, and Lam WA
- Abstract
Background: Nasopharyngeal qualitative reverse-transcription polymerase chain reaction (RT-PCR) is the gold standard for diagnosis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, but it is not practical or sufficient in every clinical scenario due to its inability to distinguish active from resolved infection. Alternative or adjunct testing may be needed to guide isolation precautions and treatment in patients admitted to the hospital., Methods: We performed a single-center, retrospective analysis of residual clinical specimens and medical record data to examine blood plasma nucleocapsid antigen as a candidate biomarker of active SARS-CoV-2. Adult patients admitted to the hospital or presenting to the emergency department with SARS-CoV-2 ribonucleic acid (RNA) detected by RT-PCR from a nasopharyngeal swab specimen were included. Both nasopharyngeal swab and a paired whole blood sample were required to be available for analysis., Results: Fifty-four patients were included. Eight patients had positive nasopharyngeal swab virus cultures, 7 of whom (87.5%) had concurrent antigenemia. Nineteen (79.2%) of 24 patients with detectable subgenomic RNA and 20 (80.0%) of 25 patients with N2 RT-PCR cycle threshold ≤ 33 had antigenemia., Conclusions: Most individuals with active SARS-CoV-2 infection are likely to have concurrent antigenemia, but there may be some individuals with active infection in whom antigenemia is not detectable. The potential for high sensitivity and convenience of a blood test prompts interest in further investigation as a screening tool to reduce reliance on nasopharyngeal swab sampling and as an adjunct diagnostic test to aid in clinical decision making during the period after acute coronavirus disease 2019., Competing Interests: Potential conflicts of interest. All authors: No reported conflicts of interest., (© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.)
- Published
- 2023
- Full Text
- View/download PDF
21. Comparison of Mid-turbinate Nasal Swabs, Saliva, and Nasopharyngeal Swabs for SARS-CoV-2 Reverse Transcription-Polymerase Chain Reaction Testing in Pediatric Outpatients.
- Author
-
Vos MB, Gonzalez MD, Stone C, Cleeton R, Figueroa J, Jerris R, Park SI, Heilman S, Nayee R, Chahroudi A, Schoof N, Mavigner M, Morris CR, Leong T, Grindle A, Westbrook A, Lam W, and Rogers BB
- Subjects
- COVID-19 Testing, Child, Humans, Nasopharynx, Outpatients, Polymerase Chain Reaction, Reverse Transcriptase Polymerase Chain Reaction, Reverse Transcription, Saliva, Specimen Handling methods, Turbinates, Young Adult, COVID-19 diagnosis, SARS-CoV-2 genetics
- Abstract
Context.—: Diagnostic testing for SARS-CoV-2 in symptomatic and asymptomatic children remains integral to care, particularly for supporting return to and attendance in schools. The concordance of SARS-CoV-2 detection in children, using various specimen types, has not been widely studied., Objective.—: To compare 3 sample types for SARS-CoV-2 polymerase chain reaction (PCR) testing in children, collected and tested at a single facility., Design.—: We prospectively recruited 142 symptomatic and asymptomatic children/young adults into a sample comparison study performed in a single health care system. Each child provided self-collected saliva, and a trained health care provider collected a mid-turbinate nasal swab and nasopharyngeal (NP) swab. Specimens were assayed within 24 hours of collection by using reverse transcription-polymerase chain reaction (RT-PCR) to detect SARS-CoV-2 on a single testing platform., Results.—: Concurrently collected saliva and mid-turbinate swabs had greater than 95% positive agreement with NP swabs when obtained within 10 days of symptom onset. Positive agreement of saliva and mid-turbinate samples collected from children with symptom onset >10 days prior, or without symptoms, was 82% compared to NP swab samples. Cycle threshold (Ct) values for mid-turbinate nasal samples more closely correlated with Ct values from NP samples than from saliva samples., Conclusions.—: These findings suggest that all 3 sample types from children are useful for SARS-CoV-2 diagnostic testing by RT-PCR, and that concordance is greatest when the child has had symptoms of COVID-19 within the past 10 days. This study provides scientific justification for using sample types other than the NP swab for SARS-CoV-2 testing in pediatric populations., Competing Interests: This work was supported by a grant from the National Institutes of Health for Rapid Acceleration of Diagnostics (RADx).
- Published
- 2022
- Full Text
- View/download PDF
22. Altered Response Pattern following AZD5582 Treatment of SIV-Infected, ART-Suppressed Rhesus Macaque Infants.
- Author
-
Bricker KM, Obregon-Perko V, Williams B, Oliver D, Uddin F, Neja M, Hopkins L, Dashti A, Jean S, Wood JS, Ehnert S, Liang S, Vanderford T, Tharp GK, Bosinger SE, Schauer AP, Mavigner M, Cottrell ML, Margolis D, Dunham RM, and Chahroudi A
- Subjects
- Alkynes pharmacokinetics, Alkynes pharmacology, Alkynes therapeutic use, Animals, Anti-Retroviral Agents pharmacokinetics, Anti-Retroviral Agents pharmacology, Anti-Retroviral Agents therapeutic use, CD4-Positive T-Lymphocytes, Humans, Macaca mulatta, Oligopeptides pharmacokinetics, Oligopeptides pharmacology, Oligopeptides therapeutic use, Viral Load, Virus Latency drug effects, Virus Replication, HIV Infections drug therapy, HIV-1 genetics, Simian Acquired Immunodeficiency Syndrome drug therapy, Simian Acquired Immunodeficiency Syndrome immunology, Simian Immunodeficiency Virus
- Abstract
The "shock and kill" strategy for HIV-1 cure incorporates latency-reversing agents (LRA) in combination with interventions that aid the host immune system in clearing virally reactivated cells. LRAs have not yet been investigated in pediatric clinical or preclinical studies. Here, we evaluated an inhibitor of apoptosis protein (IAP) inhibitor (IAPi), AZD5582, that activates the noncanonical NF-κB (ncNF-κB) signaling pathway to reverse latency. Ten weekly doses of AZD5582 were intravenously administered at 0.1 mg/kg to rhesus macaque (RM) infants orally infected with SIV
mac251 at 4 weeks of age and treated with a triple ART regimen for over 1 year. During AZD5582 treatment, on-ART viremia above the limit of detection (LOD, 60 copies/mL) was observed in 5/8 infant RMs starting at 3 days post-dose 4 and peaking at 771 copies/mL. Of the 135 measurements during AZD5582 treatment in these 5 RM infants, only 8 were above the LOD (6%), lower than the 46% we have previously reported in adult RMs. Pharmacokinetic analysis of plasma AZD5582 levels revealed a lower Cmax in treated infants compared to adults (294 ng/mL versus 802 ng/mL). RNA-Sequencing of CD4+ T cells comparing pre- and post-AZD5582 dosing showed many genes that were similarly upregulated in infants and adults, but the expression of key ncNF-κB genes, including NFKB2 and RELB , was significantly higher in adult RMs. Our results suggest that dosing modifications for this latency reversal approach may be necessary to maximize virus reactivation in the pediatric setting for successful "shock and kill" strategies. IMPORTANCE While antiretroviral therapy (ART) has improved HIV-1 disease outcome and reduced transmission, interruption of ART results in rapid viral rebound due to the persistent latent reservoir. Interventions to reduce the viral reservoir are of critical importance, especially for children who must adhere to lifelong ART to prevent disease progression. Here, we used our previously established pediatric nonhuman primate model of oral SIV infection to evaluate AZD5582, identified as a potent latency-reversing agent in adult macaques, in the controlled setting of daily ART. We demonstrated the safety of the IAPi AZD5582 and evaluate the pharmacokinetics and pharmacodynamics of repeated dosing. The response to AZD5582 in macaque infants differed from what we previously showed in adult macaques with weaker latency reversal in infants, likely due to altered pharmacokinetics and less inducibility of infant CD4+ T cells. These data supported the contention that HIV-1 cure strategies for children are best evaluated using pediatric model systems.- Published
- 2022
- Full Text
- View/download PDF
23. Single-Amplicon Multiplex Real-Time Reverse Transcription-PCR with Tiled Probes To Detect SARS-CoV-2 spike Mutations Associated with Variants of Concern.
- Author
-
Babiker A, Immergluck K, Stampfer SD, Rao A, Bassit L, Su M, Nguyen V, Stittleburg V, Ingersoll JM, Bradley HL, Mavigner M, Schoof N, Kraft CS, Chahroudi A, Schinazi RF, Martin GS, Piantadosi A, Lam WA, and Waggoner JJ
- Subjects
- Humans, Mutation, RNA, Viral genetics, Real-Time Polymerase Chain Reaction, Reverse Transcription, COVID-19, SARS-CoV-2
- Abstract
To provide an accessible and inexpensive method to surveil for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutations, we developed a multiplex real-time reverse transcription-PCR (rRT-PCR) assay, the Spike single-nucleotide polymorphism (SNP) assay, to detect specific mutations in the spike receptor binding domain. A single primer pair was designed to amplify a 348-bp region of spike , and probes were initially designed to detect K417, E484K, and N501Y. The assay was evaluated using characterized variant sample pools and residual nasopharyngeal samples. Variant calls were confirmed by SARS-CoV-2 genome sequencing in a subset of samples. Subsequently, a fourth probe was designed to detect L452R. The lower limit of 95% detection was 2.46 to 2.48 log
10 genome equivalents (GE)/ml for the three initial targets (∼1 to 2 GE/reaction). Among 253 residual nasopharyngeal swabs with detectable SARS-CoV-2 RNA, the Spike SNP assay was positive in 238 (94.1%) samples. All 220 samples with threshold cycle ( CT ) values of <30 for the SARS-CoV-2 N2 target were detected, whereas 18/33 samples with N2 CT values of ≥30 were detected. Spike SNP results were confirmed by sequencing in 50/50 samples (100%). Addition of the 452R probe did not affect performance for the original targets. The Spike SNP assay accurately identifies SARS-CoV-2 mutations in the receptor binding domain, and it can be quickly modified to detect new mutations that emerge.- Published
- 2021
- Full Text
- View/download PDF
24. The need for new test verification and regulatory support for innovative diagnostics.
- Author
-
Roback JD, Tyburski EA, Alter D, Asakrah S, Chahroudi A, Esper A, Farmer S, Figueroa J, K Frediani J, D Gonzalez M, S Gottfried D, Guarner J, A Gupta N, S Heilman S, E Hill C, Jerris R, R Kempker R, Ingersoll J, Levy JM, Mavigner M, S Moreno C, R Morris C, J Nehl E, S Neish A, Peker D, Saakadze N, Rebolledo PA, A Rostad C, Schoof N, Suessmith A, Sullivan J, Wang YFW, Wood A, Vos MB, Brand O, Martin GS, and Lam WA
- Subjects
- COVID-19 virology, Humans, SARS-CoV-2 isolation & purification, United States, COVID-19 diagnosis, COVID-19 Testing standards, National Institutes of Health (U.S.) legislation & jurisprudence, United States Food and Drug Administration legislation & jurisprudence
- Published
- 2021
- Full Text
- View/download PDF
25. New Latency Reversing Agents for HIV-1 Cure: Insights from Nonhuman Primate Models.
- Author
-
Bricker KM, Chahroudi A, and Mavigner M
- Subjects
- Animals, Anti-HIV Agents pharmacology, CD4-Positive T-Lymphocytes immunology, CD8-Positive T-Lymphocytes immunology, Lymphocyte Depletion, Primates, Simian Immunodeficiency Virus drug effects, Virus Activation drug effects, Anti-HIV Agents therapeutic use, HIV Infections drug therapy, HIV-1 drug effects, Models, Animal, Virus Latency drug effects
- Abstract
Antiretroviral therapy (ART) controls human immunodeficiency virus 1 (HIV-1) replication and prevents disease progression but does not eradicate HIV-1. The persistence of a reservoir of latently infected cells represents the main barrier to a cure. "Shock and kill" is a promising strategy involving latency reversing agents (LRAs) to reactivate HIV-1 from latently infected cells, thus exposing the infected cells to killing by the immune system or clearance agents. Here, we review advances to the "shock and kill" strategy made through the nonhuman primate (NHP) model, highlighting recently identified latency reversing agents and approaches such as mimetics of the second mitochondrial activator of caspase (SMACm), experimental CD8+ T cell depletion, immune checkpoint blockade (ICI), and toll-like receptor (TLR) agonists. We also discuss the advantages and limits of the NHP model for HIV cure research and methods developed to evaluate the efficacy of in vivo treatment with LRAs in NHPs.
- Published
- 2021
- Full Text
- View/download PDF
26. Multidisciplinary assessment of the Abbott BinaxNOW SARS-CoV-2 point-of-care antigen test in the context of emerging viral variants and self-administration.
- Author
-
Frediani JK, Levy JM, Rao A, Bassit L, Figueroa J, Vos MB, Wood A, Jerris R, Van Leung-Pineda, Gonzalez MD, Rogers BB, Mavigner M, Schinazi RF, Schoof N, Waggoner JJ, Kempker RR, Rebolledo PA, O'Neal JW, Stone C, Chahroudi A, Morris CR, Suessmith A, Sullivan J, Farmer S, Foster A, Roback JD, Ramachandra T, Washington C, Le K, Cordero MC, Esper A, Nehl EJ, Wang YF, Tyburski EA, Martin GS, and Lam WA
- Subjects
- Humans, Limit of Detection, SARS-CoV-2, Sensitivity and Specificity, COVID-19 diagnosis, COVID-19 Serological Testing, Point-of-Care Systems, Self-Testing
- Abstract
While there has been significant progress in the development of rapid COVID-19 diagnostics, as the pandemic unfolds, new challenges have emerged, including whether these technologies can reliably detect the more infectious variants of concern and be viably deployed in non-clinical settings as "self-tests". Multidisciplinary evaluation of the Abbott BinaxNOW COVID-19 Ag Card (BinaxNOW, a widely used rapid antigen test, included limit of detection, variant detection, test performance across different age-groups, and usability with self/caregiver-administration. While BinaxNOW detected the highly infectious variants, B.1.1.7 (Alpha) first identified in the UK, B.1.351 (Beta) first identified in South Africa, P.1 (Gamma) first identified in Brazil, B.1.617.2 (Delta) first identified in India and B.1.2, a non-VOC, test sensitivity decreased with decreasing viral loads. Moreover, BinaxNOW sensitivity trended lower when devices were performed by patients/caregivers themselves compared to trained clinical staff, despite universally high usability assessments following self/caregiver-administration among different age groups. Overall, these data indicate that while BinaxNOW accurately detects the new viral variants, as rapid COVID-19 tests enter the home, their already lower sensitivities compared to RT-PCR may decrease even more due to user error., (© 2021. The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
27. Rapid progression is associated with lymphoid follicle dysfunction in SIV-infected infant rhesus macaques.
- Author
-
Wood MP, Jones CI, Lippy A, Oliver BG, Walund B, Fancher KA, Fisher BS, Wright PJ, Fuller JT, Murapa P, Habib J, Mavigner M, Chahroudi A, Sather DN, Fuller DH, and Sodora DL
- Subjects
- Animals, B-Lymphocytes immunology, B-Lymphocytes virology, Genetic Variation, Germinal Center immunology, Germinal Center virology, Humans, Interferon Type I immunology, Lymphoid Tissue immunology, Lymphoid Tissue virology, Macaca mulatta, Phenotype, Simian Acquired Immunodeficiency Syndrome pathology, Simian Acquired Immunodeficiency Syndrome virology, Simian Immunodeficiency Virus genetics, Viral Load, Disease Progression, Immunity, Humoral, Simian Acquired Immunodeficiency Syndrome immunology, Simian Immunodeficiency Virus immunology
- Abstract
HIV-infected infants are at an increased risk of progressing rapidly to AIDS in the first weeks of life. Here, we evaluated immunological and virological parameters in 25 SIV-infected infant rhesus macaques to understand the factors influencing a rapid disease outcome. Infant macaques were infected with SIVmac251 and monitored for 10 to 17 weeks post-infection. SIV-infected infants were divided into either typical (TypP) or rapid (RP) progressor groups based on levels of plasma anti-SIV antibody and viral load, with RP infants having low SIV-specific antibodies and high viral loads. Following SIV infection, 11 out of 25 infant macaques exhibited an RP phenotype. Interestingly, TypP had lower levels of total CD4 T cells, similar reductions in CD4/CD8 ratios and elevated activation of CD8 T cells, as measured by the levels of HLA-DR, compared to RP. Differences between the two groups were identified in other immune cell populations, including a failure to expand activated memory (CD21-CD27+) B cells in peripheral blood in RP infant macaques, as well as reduced levels of germinal center (GC) B cells and T follicular helper (Tfh) cells in spleens (4- and 10-weeks post-SIV). Reduced B cell proliferation in splenic germinal GCs was associated with increased SIV+ cell density and follicular type 1 interferon (IFN)-induced immune activation. Further analyses determined that at 2-weeks post SIV infection TypP infants exhibited elevated levels of the GC-inducing chemokine CXCL13 in plasma, as well as significantly lower levels of viral envelope diversity compared to RP infants. Our findings provide evidence that early viral and immunologic events following SIV infection contributes to impairment of B cells, Tfh cells and germinal center formation, ultimately impeding the development of SIV-specific antibody responses in rapidly progressing infant macaques., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2021
- Full Text
- View/download PDF
28. The RADx Tech Test Verification Core and the ACME POCT in the Evaluation of COVID-19 Testing Devices: A Model for Progress and Change.
- Author
-
Nehl E, Heilman S, Ku D, Gottfried D, Farmer S, Mannino R, Tyburski E, Sullivan J, Suessmith A, Bassit L, Figueroa J, Wood A, Leong T, Rao A, Rogers B, Jerris R, Park S, Gonzalez M, Frediani J, Morris C, Levy J, Schoof N, Mavigner M, Roback J, Herzegh K, Saakadze N, Ingersoll J, Cheedarla N, Neish A, Hanberry B, Porter C, Esper A, Kempker R, Rebolledo P, McGuinness P, Balagadde F, Gore R, Koren A, Pollock N, Rogers E, Simin K, Hafer N, Picard MA, Ghezzi C, McManus D, Buchholz B, Rostad C, Claveria V, Ramachandra T, Wang YF, Washington C, Stone C, Griffiths M, Schinazi R, Chahroudi A, Vos M, Brand O, Martin G, and Lam W
- Abstract
Faced with the COVID-19 pandemic, the US system for developing and testing technologies was challenged in unparalleled ways. This article describes the multi-institutional, transdisciplinary team of the "RADx
SM Tech Test Verification Core" and its role in expediting evaluations of COVID-19 testing devices. Expertise related to aspects of diagnostic testing was coordinated to evaluate testing devices with the goal of significantly expanding the ability to mass screen Americans to preserve lives and facilitate the safe return to work and school. Focal points included: laboratory and clinical device evaluation of the limit of viral detection, sensitivity, and specificity of devices in controlled and community settings; regulatory expertise to provide focused attention to barriers to device approval and distribution; usability testing from the perspective of patients and those using the tests to identify and overcome device limitations, and engineering assessment to evaluate robustness of design including human factors, manufacturability, and scalability., (This work is licensed under a Creative Commons Attribution 4.0 License. For more information, see https://creativecommons.org/licenses/by/4.0/.)- Published
- 2021
- Full Text
- View/download PDF
29. Latency Reversal 2.0: Giving the Immune System a Seat at the Table.
- Author
-
Singh V, Dashti A, Mavigner M, and Chahroudi A
- Subjects
- Animals, CD4-Positive T-Lymphocytes, Humans, Viremia, Virus Activation, Virus Latency, HIV Infections drug therapy, HIV-1
- Abstract
Purpose of Review: For most people living with HIV (PLWH), treatment with effective antiretroviral therapy (ART) results in suppression of viremia below the limit of detection of clinical assays, immune reconstitution, reduced immune activation, avoidance of opportunistic infections, and progression to AIDS. However, ART alone is not curative, and HIV persists in a non-replicating, latent form. In this review, we provide a historical perspective on non-specific latency reversal approaches (LRA 1.0) and summarize recent advances in latency reversal strategies that target specific signaling pathways within CD4+ T cells or other immune cells to induce expression of latent HIV (immune-based latency reversal, or LRA 2.0)., Recent Findings: The HIV reservoir is primarily composed of latently infected CD4+ T cells carrying integrated, replication-competent provirus that can give rise to rebound viremia if ART is stopped. Myeloid lineage cells also contribute to HIV latency in certain tissues; we focus here on CD4+ T cells as a sufficient body of evidence regarding latency reversal in myeloid cells is lacking. The immunomodulatory LRA 2.0 approaches we describe include pattern recognition receptor agonists, immune checkpoint inhibitors, non-canonical NF-kB stimulation, and transient CD8+ lymphocyte depletion, along with promising combination strategies. We highlight recent studies demonstrating robust latency reversal in nonhuman primate models. While significant strides have been made in terms of virus reactivation from latency, initial hopes for latency reversal alone to result in a reduction of infected cells, through viral cytopathic effect or an unboosted immune system, have not been realized and it seems clear that even effective latency reversal strategies will need to be paired with an approach that facilitates immune recognition and clearance of cells containing reactivated virus.
- Published
- 2021
- Full Text
- View/download PDF
30. CD8 lymphocyte depletion enhances the latency reversal activity of the SMAC mimetic AZD5582 in ART-suppressed SIV-infected rhesus macaques.
- Author
-
Mavigner M, Liao LE, Brooks AD, Ke R, Mattingly C, Schoof N, McBrien J, Carnathan D, Liang S, Vanderford TH, Paiardini M, Kulpa D, Lifson JD, Dunham RM, Easley KA, Margolis DM, Perelson AS, Silvestri G, and Chahroudi A
- Abstract
Inducing latency reversal to reveal infected cells to the host immune system represents a potential strategy to cure HIV infection. In separate studies, we have previously shown that CD8
+ T cells may contribute to the maintenance of viral latency and identified a novel SMAC mimetic/IAP inhibitor (AZD5582) capable of reversing HIV/SIV latency in vivo by activating the non-canonical (nc) NF-κB pathway. Here, we use AZD5582 in combination with antibody-mediated depletion of CD8α+ cells to further evaluate the role of CD8+ T cells in viral latency maintenance. Six rhesus macaques (RM) were infected with SIVmac239 and treated with ART starting at week 8 post-infection. After 84-85 weeks of ART, all animals received a single dose of the anti-CD8α depleting antibody (Ab), MT807R1 (50mg/kg, s.c.), followed by 5 weekly doses of AZD5582 (0.1 mg/kg, i.v.). Following CD8α depletion + AZD5582 combined treatment, 100% of RMs experienced on-ART viremia above 60 copies per ml of plasma. In comparator groups of ART-suppressed SIV-infected RMs treated with AZD5582 only or CD8α depletion only, on-ART viremia was experienced by 56% and 57% of the animals respectively. Furthermore, the frequency of increased viremic episodes during the treatment period was greater in the CD8α depletion + AZD5582 group as compared to other groups. Mathematical modeling of virus reactivation suggested that, in addition to viral dynamics during acute infection, CD8α depletion influenced the response to AZD5582. This work suggests that the latency reversal induced by activation of the ncNF-κB signaling pathway with AZD5582 can be enhanced by CD8α+ cell depletion., (Copyright © 2021 Mavigner et al.)- Published
- 2021
- Full Text
- View/download PDF
31. Covid-19 will not "magically disappear": Why access to widespread testing is paramount.
- Author
-
George PE, Stokes CL, Bassit LC, Chahroudi A, Figueroa J, Griffiths MA, Heilman S, Ku DN, Nehl EJ, Leong T, Levy JM, Kempker R, Mannino RG, Mavigner M, Park SI, Rao A, Rebolledo PA, Roback JD, Rogers BB, Schinazi RF, Sullivan J, Tyburski EA, Vos MB, Waggoner JJ, Wang YF, Madsen J, Wechsler DS, Joiner CH, Martin GS, and Lam WA
- Subjects
- Antigens, Viral analysis, Antigens, Viral immunology, COVID-19 epidemiology, COVID-19 Nucleic Acid Testing, Coronavirus Nucleocapsid Proteins analysis, Coronavirus Nucleocapsid Proteins immunology, Cost-Benefit Analysis, Evaluation Studies as Topic, Financing, Government, Humans, Inventions, National Institutes of Health (U.S.), Point-of-Care Testing, Public-Private Sector Partnerships organization & administration, RNA, Viral analysis, Reagent Kits, Diagnostic supply & distribution, SARS-CoV-2 immunology, Sensitivity and Specificity, Spike Glycoprotein, Coronavirus analysis, Spike Glycoprotein, Coronavirus immunology, United States epidemiology, COVID-19 diagnosis, COVID-19 Testing economics, COVID-19 Testing methods, COVID-19 Testing statistics & numerical data, Health Services Accessibility, Pandemics, SARS-CoV-2 isolation & purification
- Published
- 2021
- Full Text
- View/download PDF
32. Simian-Human Immunodeficiency Virus SHIV.C.CH505 Persistence in ART-Suppressed Infant Macaques Is Characterized by Elevated SHIV RNA in the Gut and a High Abundance of Intact SHIV DNA in Naive CD4 + T Cells.
- Author
-
Obregon-Perko V, Bricker KM, Mensah G, Uddin F, Kumar MR, Fray EJ, Siliciano RF, Schoof N, Horner A, Mavigner M, Liang S, Vanderford T, Sass J, Chan C, Berendam SJ, Bar KJ, Shaw GM, Silvestri G, Fouda GG, Permar SR, and Chahroudi A
- Subjects
- Administration, Oral, Animals, Animals, Newborn, DNA, Viral analysis, Disease Reservoirs, Female, HIV Infections immunology, HIV Infections transmission, HIV-1, Male, Monkey Diseases immunology, Monkey Diseases transmission, RNA, Viral analysis, Reassortant Viruses immunology, Simian Acquired Immunodeficiency Syndrome virology, Viral Load, Anti-Retroviral Agents therapeutic use, CD4-Positive T-Lymphocytes immunology, HIV Infections veterinary, Macaca mulatta, Monkey Diseases virology, Simian Acquired Immunodeficiency Syndrome immunology, Simian Immunodeficiency Virus immunology
- Abstract
Mother-to-child transmission of human immunodeficiency virus type 1 (HIV-1) continues to cause new pediatric cases of infection through breastfeeding, a setting where it is not always possible to initiate early antiretroviral therapy (ART). Without novel interventions that do not rely on daily ART, HIV-1-infected children face lifelong medications to control infection. A detailed analysis of virus persistence following breast milk transmission of HIV-1 and ART has not been performed. Here, we used infant rhesus macaques orally infected with simian/human immunodeficiency virus (SHIV) (SHIV.C.CH505) to identify cellular and anatomical sites of virus persistence under ART. Viral DNA was detected at similar levels in blood and tissue CD4
+ T cells after a year on ART, with virus in blood and lymphoid organs confirmed to be replication competent. Viral RNA/DNA ratios were elevated in rectal CD4+ T cells compared to those of other sites ( P ≤ 0.0001), suggesting that the gastrointestinal tract is an active site of virus transcription during ART-mediated suppression of viremia. SHIV.C.CH505 DNA was detected in multiple CD4+ T cell subsets, including cells with a naive phenotype (CD45RA+ CCR7+ CD95- ). While the frequency of naive cells harboring intact provirus was lower than in memory cells, the high abundance of naive cells in the infant CD4+ T cell pool made them a substantial source of persistent viral DNA (approximately 50% of the total CD4+ T cell reservoir), with an estimated 1:2 ratio of intact provirus to total viral DNA. This viral reservoir profile broadens our understanding of virus persistence in a relevant infant macaque model and provides insight into targets for cure-directed approaches in the pediatric population. IMPORTANCE Uncovering the sanctuaries of the long-lived HIV-1 reservoir is crucial to develop cure strategies. Pediatric immunity is distinct from that of adults, which may alter where the reservoir is established in infancy. Thus, it is important to utilize pediatric models to inform cure-directed approaches for HIV-1-infected children. We used an infant rhesus macaque model of HIV-1 infection via breastfeeding to identify key sites of viral persistence under antiretroviral therapy (ART). The gastrointestinal tract was found to be a site for low-level viral transcription during ART. We also show that naive CD4+ T cells harbored intact provirus and were a major contributor to blood and lymphoid reservoir size. This is particularly striking, as memory CD4+ T cells are generally regarded as the main source of latent HIV/simian immunodeficiency virus (SIV) infection of adult humans and rhesus macaques. Our findings highlight unique features of reservoir composition in pediatric infection that should be considered for eradication efforts., (Copyright © 2020 Obregon-Perko et al.)- Published
- 2020
- Full Text
- View/download PDF
33. SMAC Mimetic Plus Triple-Combination Bispecific HIVxCD3 Retargeting Molecules in SHIV.C.CH505-Infected, Antiretroviral Therapy-Suppressed Rhesus Macaques.
- Author
-
Dashti A, Waller C, Mavigner M, Schoof N, Bar KJ, Shaw GM, Vanderford TH, Liang S, Lifson JD, Dunham RM, Ferrari G, Tuyishime M, Lam CK, Nordstrom JL, Margolis DM, Silvestri G, and Chahroudi A
- Subjects
- Animals, CD4-Positive T-Lymphocytes drug effects, CD4-Positive T-Lymphocytes immunology, CD4-Positive T-Lymphocytes virology, Female, Gene Expression Regulation, HIV Infections genetics, HIV Infections immunology, HIV Infections virology, HIV-1 drug effects, HIV-1 growth & development, HIV-1 immunology, Humans, Inhibitor of Apoptosis Proteins antagonists & inhibitors, Inhibitor of Apoptosis Proteins genetics, Inhibitor of Apoptosis Proteins immunology, Macaca mulatta, NF-kappa B genetics, NF-kappa B immunology, Reassortant Viruses drug effects, Reassortant Viruses growth & development, Reassortant Viruses immunology, Simian Acquired Immunodeficiency Syndrome genetics, Simian Acquired Immunodeficiency Syndrome immunology, Simian Acquired Immunodeficiency Syndrome virology, Simian Immunodeficiency Virus drug effects, Simian Immunodeficiency Virus growth & development, Simian Immunodeficiency Virus immunology, Viral Load drug effects, Viremia genetics, Viremia immunology, Viremia virology, Virus Latency drug effects, Virus Replication drug effects, Alkynes pharmacology, Anti-Retroviral Agents pharmacology, Antibodies, Neutralizing pharmacology, Antibodies, Viral pharmacology, HIV Infections drug therapy, Oligopeptides pharmacology, Simian Acquired Immunodeficiency Syndrome drug therapy, Viremia drug therapy
- Abstract
The "shock-and-kill" human immunodeficiency virus type 1 (HIV-1) cure strategy involves latency reversal followed by immune-mediated clearance of infected cells. We have previously shown that activation of the noncanonical NF-κB pathway using an inhibitor of apoptosis (IAP), AZD5582, reverses HIV/simian immunodeficiency virus (SIV) latency. Here, we combined AZD5582 with bispecific HIVxCD3 DART molecules to determine the impact of this approach on persistence. Rhesus macaques (RMs) ( n = 13) were infected with simian/human immunodeficiency virus SHIV.C.CH505.375H.dCT, and triple antiretroviral therapy (ART) was initiated after 16 weeks. After 42 weeks of ART, 8 RMs received a cocktail of 3 HIVxCD3 DART molecules having human A32, 7B2, or PGT145 anti-HIV-1 envelope (Env) specificities paired with a human anti-CD3 specificity that is rhesus cross-reactive. The remaining 5 ART-suppressed RMs served as controls. For 10 weeks, a DART molecule cocktail was administered weekly (each molecule at 1 mg/kg of body weight), followed 2 days later by AZD5582 (0.1 mg/kg). DART molecule serum concentrations were well above those considered adequate for redirected killing activity against Env-expressing target cells but began to decline after 3 to 6 weekly doses, coincident with the development of antidrug antibodies (ADAs) against each of the DART molecules. The combination of AZD5582 and the DART molecule cocktail did not increase on-ART viremia or cell-associated SHIV RNA in CD4
+ T cells and did not reduce the viral reservoir size in animals on ART. The lack of latency reversal in the model used in this study may be related to low pre-ART viral loads (median, <105 copies/ml) and low preintervention reservoir sizes (median, <102 SHIV DNA copies/million blood CD4+ T cells). Future studies to assess the efficacy of Env-targeting DART molecules or other clearance agents to reduce viral reservoirs after latency reversal may be more suited to models that better minimize immunogenicity and have a greater viral burden. IMPORTANCE The most significant barrier to an HIV-1 cure is the existence of the latently infected viral reservoir that gives rise to rebound viremia upon cessation of ART. Here, we tested a novel combination approach of latency reversal with AZD5582 and clearance with bispecific HIVxCD3 DART molecules in SHIV.C.CH505-infected, ART-suppressed rhesus macaques. We demonstrate that the DART molecules were not capable of clearing infected cells in vivo , attributed to the lack of quantifiable latency reversal in this model with low levels of persistent SHIV DNA prior to intervention as well as DART molecule immunogenicity., (Copyright © 2020 American Society for Microbiology.)- Published
- 2020
- Full Text
- View/download PDF
34. Long-term alterations in brain and behavior after postnatal Zika virus infection in infant macaques.
- Author
-
Raper J, Kovacs-Balint Z, Mavigner M, Gumber S, Burke MW, Habib J, Mattingly C, Fair D, Earl E, Feczko E, Styner M, Jean SM, Cohen JK, Suthar MS, Sanchez MM, Alvarado MC, and Chahroudi A
- Subjects
- Animals, Brain diagnostic imaging, Brain physiopathology, Cognition physiology, Disease Models, Animal, Female, Macaca mulatta, Memory physiology, Nerve Net diagnostic imaging, Nerve Net pathology, Nerve Net physiopathology, Neuroimaging, Social Behavior, Zika Virus physiology, Zika Virus Infection diagnostic imaging, Zika Virus Infection physiopathology, Brain pathology, Zika Virus Infection pathology, Zika Virus Infection psychology
- Abstract
Zika virus (ZIKV) infection has a profound impact on the fetal nervous system. The postnatal period is also a time of rapid brain growth, and it is important to understand the potential neurobehavioral consequences of ZIKV infection during infancy. Here we show that postnatal ZIKV infection in a rhesus macaque model resulted in long-term behavioral, motor, and cognitive changes, including increased emotional reactivity, decreased social contact, loss of balance, and deficits in visual recognition memory at one year of age. Structural and functional MRI showed that ZIKV-infected infant rhesus macaques had persistent enlargement of lateral ventricles, smaller volumes and altered functional connectivity between brain areas important for socioemotional behavior, cognitive, and motor function (e.g. amygdala, hippocampus, cerebellum). Neuropathological changes corresponded with neuroimaging results and were consistent with the behavioral and memory deficits. Overall, this study demonstrates that postnatal ZIKV infection in this model may have long-lasting neurodevelopmental consequences.
- Published
- 2020
- Full Text
- View/download PDF
35. Correction for Mavigner et al., "Simian Immunodeficiency Virus Persistence in Cellular and Anatomic Reservoirs in Antiretroviral Therapy-Suppressed Infant Rhesus Macaques".
- Author
-
Mavigner M, Habib J, Deleage C, Rosen E, Mattingly C, Bricker K, Kashuba A, Amblard F, Schinazi RF, Lawson B, Vanderford TH, Jean S, Cohen J, McGary C, Paiardini M, Wood MP, Sodora DL, Silvestri G, Estes J, and Chahroudi A
- Published
- 2020
- Full Text
- View/download PDF
36. Author Correction: Robust and persistent reactivation of SIV and HIV by N-803 and depletion of CD8 + cells.
- Author
-
McBrien JB, Mavigner M, Franchitti L, Smith SA, White E, Tharp GK, Walum H, Busman-Sahay K, Aguilera-Sandoval CR, Thayer WO, Spagnuolo RA, Kovarova M, Wahl A, Cervasi B, Margolis DM, Vanderford TH, Carnathan DG, Paiardini M, Lifson JD, Lee JH, Safrit JT, Bosinger SE, Estes JD, Derdeyn CA, Garcia JV, Kulpa DA, Chahroudi A, and Silvestri G
- Abstract
An Amendment to this paper has been published and can be accessed via a link at the top of the paper.
- Published
- 2020
- Full Text
- View/download PDF
37. Robust and persistent reactivation of SIV and HIV by N-803 and depletion of CD8 + cells.
- Author
-
McBrien JB, Mavigner M, Franchitti L, Smith SA, White E, Tharp GK, Walum H, Busman-Sahay K, Aguilera-Sandoval CR, Thayer WO, Spagnuolo RA, Kovarova M, Wahl A, Cervasi B, Margolis DM, Vanderford TH, Carnathan DG, Paiardini M, Lifson JD, Lee JH, Safrit JT, Bosinger SE, Estes JD, Derdeyn CA, Garcia JV, Kulpa DA, Chahroudi A, and Silvestri G
- Subjects
- Animals, CD4-Positive T-Lymphocytes virology, HIV Infections immunology, HIV Infections virology, Humans, Interleukin-15 immunology, Lymphocyte Depletion, Macaca mulatta, Mice, Simian Acquired Immunodeficiency Syndrome immunology, Simian Acquired Immunodeficiency Syndrome virology, Virus Latency, CD8-Positive T-Lymphocytes immunology, Interleukin-15 agonists, Simian Immunodeficiency Virus physiology, Virus Replication immunology
- Abstract
Human immunodeficiency virus (HIV) persists indefinitely in individuals with HIV who receive antiretroviral therapy (ART) owing to a reservoir of latently infected cells that contain replication-competent virus
1-4 . Here, to better understand the mechanisms responsible for latency persistence and reversal, we used the interleukin-15 superagonist N-803 in conjunction with the depletion of CD8+ lymphocytes in ART-treated macaques infected with simian immunodeficiency virus (SIV). Although N-803 alone did not reactivate virus production, its administration after the depletion of CD8+ lymphocytes in conjunction with ART treatment induced robust and persistent reactivation of the virus in vivo. We found viraemia of more than 60 copies per ml in all macaques (n = 14; 100%) and in 41 out of a total of 56 samples (73.2%) that were collected each week after N-803 administration. Notably, concordant results were obtained in ART-treated HIV-infected humanized mice. In addition, we observed that co-culture with CD8+ T cells blocked the in vitro latency-reversing effect of N-803 on primary human CD4+ T cells that were latently infected with HIV. These results advance our understanding of the mechanisms responsible for latency reversal and lentivirus reactivation during ART-suppressed infection.- Published
- 2020
- Full Text
- View/download PDF
38. Systemic HIV and SIV latency reversal via non-canonical NF-κB signalling in vivo.
- Author
-
Nixon CC, Mavigner M, Sampey GC, Brooks AD, Spagnuolo RA, Irlbeck DM, Mattingly C, Ho PT, Schoof N, Cammon CG, Tharp GK, Kanke M, Wang Z, Cleary RA, Upadhyay AA, De C, Wills SR, Falcinelli SD, Galardi C, Walum H, Schramm NJ, Deutsch J, Lifson JD, Fennessey CM, Keele BF, Jean S, Maguire S, Liao B, Browne EP, Ferris RG, Brehm JH, Favre D, Vanderford TH, Bosinger SE, Jones CD, Routy JP, Archin NM, Margolis DM, Wahl A, Dunham RM, Silvestri G, Chahroudi A, and Garcia JV
- Subjects
- Alkynes pharmacology, Animals, Anti-Retroviral Agents pharmacology, HIV Infections metabolism, HIV-1 drug effects, Macaca mulatta, Mice, Oligopeptides pharmacology, Simian Acquired Immunodeficiency Syndrome metabolism, Simian Immunodeficiency Virus drug effects, HIV Infections virology, HIV-1 physiology, NF-kappa B metabolism, Simian Acquired Immunodeficiency Syndrome virology, Simian Immunodeficiency Virus physiology, Virus Latency drug effects
- Abstract
Long-lasting, latently infected resting CD4
+ T cells are the greatest obstacle to obtaining a cure for HIV infection, as these cells can persist despite decades of treatment with antiretroviral therapy (ART). Estimates indicate that more than 70 years of continuous, fully suppressive ART are needed to eliminate the HIV reservoir1 . Alternatively, induction of HIV from its latent state could accelerate the decrease in the reservoir, thus reducing the time to eradication. Previous attempts to reactivate latent HIV in preclinical animal models and in clinical trials have measured HIV induction in the peripheral blood with minimal focus on tissue reservoirs and have had limited effect2-9 . Here we show that activation of the non-canonical NF-κB signalling pathway by AZD5582 results in the induction of HIV and SIV RNA expression in the blood and tissues of ART-suppressed bone-marrow-liver-thymus (BLT) humanized mice and rhesus macaques infected with HIV and SIV, respectively. Analysis of resting CD4+ T cells from tissues after AZD5582 treatment revealed increased SIV RNA expression in the lymph nodes of macaques and robust induction of HIV in almost all tissues analysed in humanized mice, including the lymph nodes, thymus, bone marrow, liver and lung. This promising approach to latency reversal-in combination with appropriate tools for systemic clearance of persistent HIV infection-greatly increases opportunities for HIV eradication.- Published
- 2020
- Full Text
- View/download PDF
39. Analytical Treatment Interruption after Short-Term Antiretroviral Therapy in a Postnatally Simian-Human Immunodeficiency Virus-Infected Infant Rhesus Macaque Model.
- Author
-
Goswami R, Nelson AN, Tu JJ, Dennis M, Feng L, Kumar A, Mangold J, Mangan RJ, Mattingly C, Curtis AD 2nd, Obregon-Perko V, Mavigner M, Pollara J, Shaw GM, Bar KJ, Chahroudi A, De Paris K, Chan C, Van Rompay KKA, and Permar SR
- Subjects
- Animals, Biomarkers, CD4-Positive T-Lymphocytes, Disease Models, Animal, Humans, Immunoglobulin G blood, Kinetics, Macaca mulatta, Simian Acquired Immunodeficiency Syndrome immunology, Simian Acquired Immunodeficiency Syndrome virology, Simian Immunodeficiency Virus genetics, Viral Load, Virus Replication drug effects, env Gene Products, Human Immunodeficiency Virus immunology, Anti-Retroviral Agents immunology, Anti-Retroviral Agents pharmacology, Simian Acquired Immunodeficiency Syndrome drug therapy, Simian Immunodeficiency Virus drug effects
- Abstract
To achieve long-term viral remission in human immunodeficiency virus (HIV)-infected children, novel strategies beyond early antiretroviral therapy (ART) will be necessary. Identifying clinical predictors of the time to viral rebound upon ART interruption will streamline the development of novel therapeutic strategies and accelerate their evaluation in clinical trials. However, identification of these biomarkers is logistically challenging in infants, due to sampling limitations and the potential risks of treatment interruption. To facilitate the identification of biomarkers predicting viral rebound, we have developed an infant rhesus macaque (RM) model of oral simian-human immunodeficiency virus (SHIV) SHIV.CH505.375H.dCT challenge and analytical treatment interruption (ATI) after short-term ART. We used this model to characterize SHIV replication kinetics and virus-specific immune responses during short-term ART or after ATI and demonstrated plasma viral rebound in 5 out of 6 (83%) infants. We observed a decline in humoral immune responses and partial dampening of systemic immune activation upon initiation of ART in these infants. Furthermore, we monitored SHIV replication and rebound kinetics in infant and adult RMs and found that both infants and adults demonstrated equally potent virus-specific humoral immune responses. Finally, we validated our models by confirming a well-established correlate of the time to viral rebound, namely, the pre-ART plasma viral load, as well as identified additional potential humoral immune correlates. Thus, this model of infant ART and viral rebound can be used and further optimized to define biomarkers of viral rebound following long-term ART as well as to preclinically assess novel therapies to achieve a pediatric HIV functional cure. IMPORTANCE Novel interventions that do not rely on daily adherence to ART are needed to achieve sustained viral remission for perinatally infected children, who currently rely on lifelong ART. Considering the risks and expense associated with ART interruption trials, the identification of biomarkers of viral rebound will prioritize promising therapeutic intervention strategies, including anti-HIV Env protein therapeutics. However, comprehensive studies to identify those biomarkers are logistically challenging in human infants, demanding the need for relevant nonhuman primate models of HIV rebound. In this study, we developed an infant RM model of oral infection with simian-human immunodeficiency virus expressing clade C HIV Env and short-term ART followed by ATI, longitudinally characterizing the immune responses to viral infection during ART and after ATI. Additionally, we compared this infant RM model to an analogous adult RM rebound model and identified virologic and immunologic correlates of the time to viral rebound after ATI., (Copyright © 2019 Goswami et al.)
- Published
- 2019
- Full Text
- View/download PDF
40. Correction for Mavigner et al., "Simian Immunodeficiency Virus Persistence in Cellular and Anatomic Reservoirs in Antiretroviral Therapy-Suppressed Infant Rhesus Macaques".
- Author
-
Mavigner M, Habib J, Deleage C, Rosen E, Mattingly C, Bricker K, Kashuba A, Amblard F, Schinazi RF, Lawson B, Vanderford TH, Jean S, Cohen J, McGary C, Paiardini M, Wood MP, Sodora DL, Silvestri G, Estes J, and Chahroudi A
- Published
- 2019
- Full Text
- View/download PDF
41. Antibody-Mediated CD4 Depletion Induces Homeostatic CD4 + T Cell Proliferation without Detectable Virus Reactivation in Antiretroviral Therapy-Treated Simian Immunodeficiency Virus-Infected Macaques.
- Author
-
Kumar NA, McBrien JB, Carnathan DG, Mavigner M, Mattingly C, White ER, Viviano F, Bosinger SE, Chahroudi A, Silvestri G, Paiardini M, and Vanderford TH
- Subjects
- Animals, Anti-Retroviral Agents pharmacology, Macaca mulatta, Simian Acquired Immunodeficiency Syndrome immunology, Simian Immunodeficiency Virus immunology, Viral Load, Viremia, CD4-Positive T-Lymphocytes immunology, Cell Proliferation physiology, Lymphocyte Depletion methods, Simian Immunodeficiency Virus growth & development, Virus Activation physiology, Virus Latency physiology, Virus Replication physiology
- Abstract
A major barrier to human immunodeficiency virus (HIV) eradication is the long-term persistence of latently infected CD4
+ T cells harboring integrated replication-competent virus. It has been proposed that the homeostatic proliferation of these cells drives long-term reservoir persistence in the absence of virus reactivation, thus avoiding cell death due to either virus-mediated cytopathicity or immune effector mechanisms. Here, we conducted an experimental depletion of CD4+ T cells in eight antiretroviral therapy (ART)-treated, simian immunodeficiency virus (SIV)-infected rhesus macaques (RMs) to determine whether the homeostatically driven CD4+ T-cell proliferation that follows CD4+ T-cell depletion results in reactivation of latent virus and/or expansion of the virus reservoir. After administration of the CD4R1 antibody, we observed a CD4+ T cell depletion of 65 to 89% in peripheral blood and 20 to 50% in lymph nodes, followed by a significant increase in CD4+ T cell proliferation during CD4+ T cell reconstitution. However, this CD4+ T cell proliferation was not associated with detectable increases in viremia, indicating that the homeostatic activation of CD4+ T cells is not sufficient to induce virus reactivation from latently infected cells. Interestingly, the homeostatic reconstitution of the CD4+ T cell pool was not associated with significant changes in the number of circulating cells harboring SIV DNA compared to results for the first postdepletion time point. This study indicates that, in ART-treated SIV-infected RMs, the homeostasis-driven CD4+ T-cell proliferation that follows experimental CD4+ T-cell depletion occurs in the absence of detectable reactivation of latent virus and does not increase the size of the virus reservoir as measured in circulating cells. IMPORTANCE Despite successful suppression of HIV replication with antiretroviral therapy, current treatments are unable to eradicate the latent virus reservoir, and treatment interruption almost invariably results in the reactivation of HIV even after decades of virus suppression. Homeostatic proliferation of latently infected cells is one mechanism that could maintain the latent reservoir. To understand the impact of homeostatic mechanisms on virus reactivation and reservoir size, we experimentally depleted CD4+ T cells in ART-treated SIV-infected rhesus macaques and monitored their homeostatic rebound. We find that depletion-induced proliferation of CD4+ T cells is insufficient to reactivate the viral reservoir in vivo Furthermore, the proportion of SIV DNA+ CD4+ T cells remains unchanged during reconstitution, suggesting that the reservoir is resistant to this mechanism of expansion at least in this experimental system. Understanding how T cell homeostasis impacts latent reservoir longevity could lead to the development of new treatment paradigms aimed at curing HIV infection., (Copyright © 2018 American Society for Microbiology.)- Published
- 2018
- Full Text
- View/download PDF
42. Simian Immunodeficiency Virus Persistence in Cellular and Anatomic Reservoirs in Antiretroviral Therapy-Suppressed Infant Rhesus Macaques.
- Author
-
Mavigner M, Habib J, Deleage C, Rosen E, Mattingly C, Bricker K, Kashuba A, Amblard F, Schinazi RF, Lawson B, Vanderford TH, Jean S, Cohen J, McGary C, Paiardini M, Wood MP, Sodora DL, Silvestri G, Estes J, and Chahroudi A
- Subjects
- Animals, CD4 Lymphocyte Count, Cross-Sectional Studies, Disease Reservoirs, Lymph Nodes immunology, Lymph Nodes virology, Macaca mulatta, Simian Acquired Immunodeficiency Syndrome immunology, Simian Acquired Immunodeficiency Syndrome transmission, Simian Acquired Immunodeficiency Syndrome virology, Simian Immunodeficiency Virus immunology, Simian Immunodeficiency Virus physiology, Antiretroviral Therapy, Highly Active adverse effects, Infectious Disease Transmission, Vertical veterinary, Simian Acquired Immunodeficiency Syndrome blood, Simian Immunodeficiency Virus isolation & purification, Viral Load drug effects
- Abstract
Worldwide, nearly two million children are infected with human immunodeficiency virus (HIV), with breastfeeding accounting for the majority of contemporary HIV transmissions. Antiretroviral therapy (ART) has reduced HIV-related morbidity and mortality but is not curative. The main barrier to a cure is persistence of latent HIV in long-lived reservoirs. However, our understanding of the cellular and anatomic sources of the HIV reservoir during infancy and childhood is limited. Here, we developed a pediatric model of ART suppression in orally simian immunodeficiency virus (SIV)-infected rhesus macaque (RM) infants, with measurement of virus persistence in blood and tissues after 6 to 9 months of ART. Cross-sectional analyses were conducted to compare SIV RNA and DNA levels in adult and infant RMs naive to treatment and on ART. We demonstrate efficient viral suppression following ART initiation in SIV-infected RM infants with sustained undetectable plasma viral loads in the setting of heterogeneous penetration of ART into lymphoid and gastrointestinal tissues and low drug levels in the brain. We further show reduction in SIV RNA and DNA on ART in lymphoid tissues of both infant and adult RMs but stable (albeit low) levels of SIV RNA and DNA in the brains of viremic and ART-suppressed infants. Finally, we report a large contribution of naive CD4
+ T cells to the total CD4 reservoir of SIV in blood and lymph nodes of ART-suppressed RM infants that differs from what we show in adults. These results reveal important aspects of HIV/SIV persistence in infants and provide insight into strategic targets for cure interventions in a pediatric population. IMPORTANCE While antiretroviral therapy (ART) can reduce HIV replication, the virus cannot be eradicated from an infected individual, and our incomplete understanding of HIV persistence in reservoirs greatly complicates the generation of a cure for HIV infection. Given the immaturity of the infant immune system, it is critically important to study HIV reservoirs specifically in this population. Here, we established a pediatric animal model to simulate breastfeeding transmission and study SIV reservoirs in rhesus macaque (RM) infants. Our study demonstrates that ART can be safely administered to infant RMs for prolonged periods and that it efficiently controls viral replication in this model. SIV persistence was shown in blood and tissues, with similar anatomic distributions of SIV reservoirs in infant and adult RMs. However, in the peripheral blood and lymph nodes, a greater contribution of the naive CD4+ T cells to the SIV reservoir was observed in infants than in adults., (Copyright © 2018 American Society for Microbiology.)- Published
- 2018
- Full Text
- View/download PDF
43. Short-Term Pegylated Interferon α2a Treatment Does Not Significantly Reduce the Viral Reservoir of Simian Immunodeficiency Virus-Infected, Antiretroviral Therapy-Treated Rhesus Macaques.
- Author
-
Palesch D, Bosinger SE, Mavigner M, Billingsley JM, Mattingly C, Carnathan DG, Paiardini M, Chahroudi A, Vanderford TH, and Silvestri G
- Subjects
- Animals, Cells, Cultured, Macaca mulatta, Male, Recombinant Proteins pharmacology, Simian Acquired Immunodeficiency Syndrome drug therapy, Simian Acquired Immunodeficiency Syndrome immunology, T-Lymphocytes drug effects, T-Lymphocytes immunology, Viral Load drug effects, Viremia drug therapy, Antiviral Agents pharmacology, Interferon-alpha pharmacology, Polyethylene Glycols pharmacology, Simian Acquired Immunodeficiency Syndrome virology, Simian Immunodeficiency Virus drug effects, T-Lymphocytes virology, Viremia virology, Virus Replication drug effects
- Abstract
The major obstacle to human immunodeficiency type 1 (HIV-1) eradication is a reservoir of latently infected cells that persists despite long-term antiretroviral therapy (ART) and causes rapid viral rebound if treatment is interrupted. Type I interferons are immunomodulatory cytokines that induce antiviral factors and have been evaluated for the treatment of HIV-infected individuals, resulting in moderate reduction of viremia and inconclusive data about their effect on reservoir size. Here, we assessed the potential of pegylated IFN-α2a (pIFN-α2a) to reduce the viral reservoir in simian immunodeficiency virus (SIV)-infected, ART-treated rhesus macaques (RMs). We found that pIFN-α2a treatment of animals in which virus replication is effectively suppressed with ART is safe and well tolerated, as no major clinical side effects were observed. By monitoring the cellular immune response during this intervention, we established that pIFN-α2a administration is not associated with either CD4
+ T cell depletion or increased immune activation. Importantly, we found that interferon-stimulated genes (ISGs) were significantly upregulated in IFN-treated RMs compared to control animals, confirming that pIFN-α2a is bioactive in vivo To evaluate the effect of pIFN-α2a administration on the viral reservoir in CD4+ T cells, we performed cell-associated proviral SIV DNA measurements in multiple tissues and assessed levels of replication-competent virus by a quantitative viral outgrowth assay (QVOA). These analyses failed to reveal any significant difference in reservoir size between IFN-treated and control animals. In summary, our data suggest that short-term type I interferon treatment in combination with suppressive ART is not sufficient to induce a significant reduction of the viral reservoir in SIV-infected RMs. IMPORTANCE The potential of type I interferons to reduce the viral reservoir has been recently studied in clinical trials in HIV-infected humans. However, given the lack of mechanistic data and the potential for safety concerns, a more comprehensive testing of IFN treatment in vivo in SIV-infected RMs is critical to provide rationale for further development of this intervention in humans. Utilizing the SIV/RM model in which virus replication is suppressed with ART, we addressed experimental limitations of previous human studies, in particular the lack of a control group and specimen sampling limited to blood. Here, we show by rigorous testing of blood and lymphoid tissues that virus replication and reservoir size were not significantly affected by pIFN-α2a treatment in SIV-infected, ART-treated RMs. This suggests that intensified and/or prolonged IFN treatment regimens, possibly in combination with other antilatency agents, are necessary to effectively purge the HIV/SIV reservoir under ART., (Copyright © 2018 American Society for Microbiology.)- Published
- 2018
- Full Text
- View/download PDF
44. Postnatal Zika virus infection is associated with persistent abnormalities in brain structure, function, and behavior in infant macaques.
- Author
-
Mavigner M, Raper J, Kovacs-Balint Z, Gumber S, O'Neal JT, Bhaumik SK, Zhang X, Habib J, Mattingly C, McDonald CE, Avanzato V, Burke MW, Magnani DM, Bailey VK, Watkins DI, Vanderford TH, Fair D, Earl E, Feczko E, Styner M, Jean SM, Cohen JK, Silvestri G, Johnson RP, O'Connor DH, Wrammert J, Suthar MS, Sanchez MM, Alvarado MC, and Chahroudi A
- Subjects
- Animals, Animals, Newborn, Brain diagnostic imaging, Brain physiopathology, Female, Macaca mulatta, Magnetic Resonance Imaging, Male, Pregnancy, RNA, Viral genetics, Zika Virus Infection diagnostic imaging, Zika Virus Infection physiopathology, Brain pathology, Brain virology, Zika Virus Infection complications, Zika Virus Infection pathology
- Abstract
The Zika virus (ZIKV) epidemic is associated with fetal brain lesions and other serious birth defects classified as congenital ZIKV syndrome. Postnatal ZIKV infection in infants and children has been reported; however, data on brain anatomy, function, and behavioral outcomes following infection are absent. We show that postnatal ZIKV infection of infant rhesus macaques (RMs) results in persistent structural and functional alterations of the central nervous system compared to age-matched controls. We demonstrate ZIKV lymphoid tropism and neurotropism in infant RMs and histopathologic abnormalities in the peripheral and central nervous systems including inflammatory infiltrates, astrogliosis, and Wallerian degeneration. Structural and resting-state functional magnetic resonance imaging (MRI/rs-fMRI) show persistent enlargement of lateral ventricles, maturational changes in specific brain regions, and altered functional connectivity (FC) between brain areas involved in emotional behavior and arousal functions, including weakened amygdala-hippocampal connectivity in two of two ZIKV-infected infant RMs several months after clearance of ZIKV RNA from peripheral blood. ZIKV infection also results in distinct alterations in the species-typical emotional reactivity to acute stress, which were predicted by the weak amygdala-hippocampal FC. We demonstrate that postnatal ZIKV infection of infants in this model affects neurodevelopment, suggesting that long-term clinical monitoring of pediatric cases is warranted., (Copyright © 2018 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.)
- Published
- 2018
- Full Text
- View/download PDF
45. Liver macrophage-associated inflammation correlates with SIV burden and is substantially reduced following cART.
- Author
-
Fisher BS, Green RR, Brown RR, Wood MP, Hensley-McBain T, Fisher C, Chang J, Miller AD, Bosche WJ, Lifson JD, Mavigner M, Miller CJ, Gale M Jr, Silvestri G, Chahroudi A, Klatt NR, and Sodora DL
- Subjects
- Animals, Anti-Retroviral Agents pharmacology, Cell Count, Cells, Cultured, Drug Therapy, Combination, Humans, Inflammation drug therapy, Inflammation virology, Liver immunology, Liver virology, Macaca mulatta, Macrophages drug effects, Simian Acquired Immunodeficiency Syndrome immunology, Simian Acquired Immunodeficiency Syndrome pathology, Simian Acquired Immunodeficiency Syndrome virology, Simian Immunodeficiency Virus physiology, Anti-Retroviral Agents administration & dosage, Inflammation pathology, Liver pathology, Macrophages pathology, Simian Acquired Immunodeficiency Syndrome drug therapy, Simian Immunodeficiency Virus drug effects, Viral Load drug effects, Viral Load immunology
- Abstract
Liver disease is a leading contributor to morbidity and mortality during HIV infection, despite the use of combination antiretroviral therapy (cART). The precise mechanisms of liver disease during HIV infection are poorly understood partially due to the difficulty in obtaining human liver samples as well as the presence of confounding factors (e.g. hepatitis co-infection, alcohol use). Utilizing the simian immunodeficiency virus (SIV) macaque model, a controlled study was conducted to evaluate the factors associated with liver inflammation and the impact of cART. We observed an increase in hepatic macrophages during untreated SIV infection that was associated with a number of inflammatory and fibrosis mediators (TNFα, CCL3, TGFβ). Moreover, an upregulation in the macrophage chemoattractant factor CCL2 was detected in the livers of SIV-infected macaques that coincided with an increase in the number of activated CD16+ monocyte/macrophages and T cells expressing the cognate receptor CCR2. Expression of Mac387 on monocyte/macrophages further indicated that these cells recently migrated to the liver. The hepatic macrophage and T cell levels strongly correlated with liver SIV DNA levels, and were not associated with the levels of 16S bacterial DNA. Utilizing in situ hybridization, SIV-infected cells were found primarily within portal triads, and were identified as T cells. Microarray analysis identified a strong antiviral transcriptomic signature in the liver during SIV infection. In contrast, macaques treated with cART exhibited lower levels of liver macrophages and had a substantial, but not complete, reduction in their inflammatory profile. In addition, residual SIV DNA and bacteria 16S DNA were detected in the livers during cART, implicating the liver as a site on-going immune activation during antiretroviral therapy. These findings provide mechanistic insights regarding how SIV infection promotes liver inflammation through macrophage recruitment, with implications for in HIV-infected individuals.
- Published
- 2018
- Full Text
- View/download PDF
46. In Vivo Models of Human Immunodeficiency Virus Persistence and Cure Strategies.
- Author
-
Nixon CC, Mavigner M, Silvestri G, and Garcia JV
- Subjects
- Animals, HIV drug effects, Humans, Primates, Anti-HIV Agents therapeutic use, Disease Models, Animal, HIV physiology, HIV Infections drug therapy, HIV Infections virology, Virus Latency drug effects
- Abstract
Current HIV therapy is not curative regardless of how soon after infection it is initiated or how long it is administered, and therapy interruption almost invariably results in robust viral rebound. Human immunodeficiency virus persistence is therefore the major obstacle to a cure for AIDS. The testing and implementation of novel yet unproven approaches to HIV eradication that could compromise the health status of HIV-infected individuals might not be ethically warranted. Therefore, adequate in vitro and in vivo evidence of efficacy is needed to facilitate the clinical implementation of promising strategies for an HIV cure. Animal models of HIV infection have a strong and well-documented history of bridging the gap between laboratory discoveries and eventual clinical implementation. More recently, animal models have been developed and implemented for the in vivo evaluation of novel HIV cure strategies. In this article, we review the recent progress in this rapidly moving area of research, focusing on the two most promising model systems: humanized mice and nonhuman primates., (© The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.)
- Published
- 2017
- Full Text
- View/download PDF
47. Dynamics of SIV-specific CXCR5+ CD8 T cells during chronic SIV infection.
- Author
-
Mylvaganam GH, Rios D, Abdelaal HM, Iyer S, Tharp G, Mavigner M, Hicks S, Chahroudi A, Ahmed R, Bosinger SE, Williams IR, Skinner PJ, Velu V, and Amara RR
- Subjects
- Animals, Chronic Disease, Macaca mulatta, Male, CD8-Positive T-Lymphocytes physiology, Germinal Center cytology, Receptors, CXCR5 metabolism, Simian Acquired Immunodeficiency Syndrome immunology, Simian Immunodeficiency Virus immunology
- Abstract
A significant challenge to HIV eradication is the elimination of viral reservoirs in germinal center (GC) T follicular helper (Tfh) cells. However, GCs are considered to be immune privileged for antiviral CD8 T cells. Here, we show a population of simian immunodeficiency virus (SIV)-specific CD8 T cells express CXCR5 (C-X-C chemokine receptor type 5, a chemokine receptor required for homing to GCs) and expand in lymph nodes (LNs) following pathogenic SIV infection in a cohort of vaccinated macaques. This expansion was greater in animals that exhibited superior control of SIV. The CXCR5+ SIV-specific CD8 T cells demonstrated enhanced polyfunctionality, restricted expansion of antigen-pulsed Tfh cells in vitro , and possessed a unique gene expression pattern related to Tfh and Th2 cells. The increase in CXCR5+ CD8 T cells was associated with the presence of higher frequencies of SIV-specific CD8 T cells in the GC. Following TCR-driven stimulation in vitro, CXCR5+ but not CXCR5- CD8 T cells generated both CXCR5+ as well as CXCR5- cells. However, the addition of TGF-β to CXCR5- CD8 T cells induced a population of CXCR5+ CD8 T cells, suggesting that this cytokine may be important in modulating these CXCR5+ CD8 T cells in vivo. Thus, CXCR5+ CD8 T cells represent a unique subset of antiviral CD8 T cells that expand in LNs during chronic SIV infection and may play a significant role in the control of pathogenic SIV infection.
- Published
- 2017
- Full Text
- View/download PDF
48. Quantifying integrated SIV-DNA by repetitive-sampling Alu-gag PCR.
- Author
-
Mavigner M, Lee ST, Habib J, Robinson C, Silvestri G, O'Doherty U, and Chahroudi A
- Abstract
Objectives: Although antiretroviral therapy (ART) effectively suppresses HIV-1 replication, it does not eradicate the virus and ART interruption consistently results in rebound of viraemia, demonstrating the persistence of a long-lived viral reservoir. Several approaches aimed at reducing virus persistence are being developed, and accurate measurements of the latent reservoir (LR) are necessary to assess the effectiveness of anti-latency interventions. We sought to measure the LR in SIV/SHIV-infected rhesus macaques (RMs) by quantifying integrated SIV-DNA., Methods: We optimised a repetitive sampling Alu-gag PCR to quantify integrated SIV-DNA ex vivo in ART-naïve and ART-experienced SIV/SHIV-infected RMs., Results: In ART-naïve RMs, we found the median level of integrated SIV-DNA to be 1660 copies and 866 copies per million PBMC during untreated acute and chronic SHIV infection, respectively. Integrated and total SIV-DNA levels were positively correlated with one another. In ART-treated RMs, integrated SIV-DNA was readily detected in lymph nodes and spleen and levels of total (3319 copies/million cells) and integrated (3160 copies/million cells) SIV-DNA were similar after a median of 404 days of ART. In peripheral blood CD4+ T cells from ART-treated RMs, levels of total (3319 copies/million cells) and integrated (2742 copies/million cells) SIV-DNA were not significantly different and were positively correlated., Conclusions: The assay described here is validated and can be used in interventional studies testing HIV/SIV cure strategies in RMs. Measurement of integrated SIV-DNA in ART-treated RMs, along with other reservoir analyses, gives an estimate of the size of the LR.
- Published
- 2016
49. Initiation of Antiretroviral Therapy Restores CD4+ T Memory Stem Cell Homeostasis in Simian Immunodeficiency Virus-Infected Macaques.
- Author
-
Cartwright EK, Palesch D, Mavigner M, Paiardini M, Chahroudi A, and Silvestri G
- Subjects
- Animals, CD4-Positive T-Lymphocytes drug effects, CD4-Positive T-Lymphocytes virology, DNA, Viral genetics, Humans, Immunologic Memory drug effects, Macaca mulatta, Primate Diseases immunology, Primate Diseases virology, Simian Acquired Immunodeficiency Syndrome immunology, Simian Acquired Immunodeficiency Syndrome virology, Simian Immunodeficiency Virus, Stem Cells drug effects, Stem Cells immunology, Stem Cells virology, T-Lymphocyte Subsets drug effects, T-Lymphocyte Subsets immunology, T-Lymphocyte Subsets virology, Viral Load, Anti-Retroviral Agents therapeutic use, CD4-Positive T-Lymphocytes immunology, Homeostasis physiology, Immunologic Memory immunology, Primate Diseases drug therapy, Simian Acquired Immunodeficiency Syndrome drug therapy, Virus Replication drug effects
- Abstract
Unlabelled: Treatment of human immunodeficiency virus (HIV) infection with antiretroviral therapy (ART) has significantly improved prognosis. Unfortunately, interruption of ART almost invariably results in viral rebound, attributed to a pool of long-lived, latently infected cells. Based on their longevity and proliferative potential, CD4(+) T memory stem cells (TSCM) have been proposed as an important site of HIV persistence. In a previous study, we found that in simian immunodeficiency virus (SIV)-infected rhesus macaques (RM), CD4(+) TSCM are preserved in number but show (i) a decrease in the frequency of CCR5(+) cells, (ii) an expansion of the fraction of proliferating Ki-67(+) cells, and (iii) high levels of SIV DNA. To understand the impact of ART on both CD4(+) TSCM homeostasis and virus persistence, we conducted a longitudinal analysis of these cells in the blood and lymph nodes of 25 SIV-infected RM. We found that ART induced a significant restoration of CD4(+) CCR5(+) TSCM both in blood and in lymph nodes and a reduction in the fraction of proliferating CD4(+) Ki-67(+) TSCM in blood (but not lymph nodes). Importantly, we found that the level of SIV DNA in CD4(+) transitional memory (TTM) and effector memory (TEM) T cells declined ∼100-fold after ART in both blood and lymph nodes, while the level of SIV DNA in CD4(+) TSCM and central memory T cells (TCM-) did not significantly change. These data suggest that ART is effective at partially restoring CD4(+) TSCM homeostasis, and the observed stable level of virus in TSCM supports the hypothesis that these cells are a critical contributor to SIV persistence., Importance: Understanding the roles of various CD4(+) T cell memory subsets in immune homeostasis and HIV/SIV persistence during antiretroviral therapy (ART) is critical to effectively treat and cure HIV infection. T memory stem cells (TSCM) are a unique memory T cell subset with enhanced self-renewal capacity and the ability to differentiate into other memory T cell subsets, such as central and transitional memory T cells (TCM and TTM, respectively). CD4(+) TSCM are disrupted but not depleted during pathogenic SIV infection. We find that ART is partially effective at restoring CD4(+) TSCM homeostasis and that SIV DNA harbored within this subset contracts more slowly than virus harbored in shorter-lived subsets, such as TTM and effector memory (TEM). Because of their ability to persist long-term in an individual, understanding the dynamics of virally infected CD4(+) TSCM during suppressive ART is important for future therapeutic interventions aimed at modulating immune activation and purging the HIV reservoir., (Copyright © 2016, American Society for Microbiology. All Rights Reserved.)
- Published
- 2016
- Full Text
- View/download PDF
50. Reduced Simian Immunodeficiency Virus Replication in Macrophages of Sooty Mangabeys Is Associated with Increased Expression of Host Restriction Factors.
- Author
-
Mir KD, Mavigner M, Wang C, Paiardini M, Sodora DL, Chahroudi AM, Bosinger SE, and Silvestri G
- Subjects
- Animals, CD4-Positive T-Lymphocytes drug effects, CD4-Positive T-Lymphocytes immunology, CD4-Positive T-Lymphocytes pathology, CD4-Positive T-Lymphocytes virology, CD8-Positive T-Lymphocytes drug effects, CD8-Positive T-Lymphocytes immunology, CD8-Positive T-Lymphocytes pathology, CD8-Positive T-Lymphocytes virology, Cercocebus atys immunology, GPI-Linked Proteins genetics, GPI-Linked Proteins immunology, Gene Expression Regulation, Host Specificity, Host-Pathogen Interactions, Interferon-alpha pharmacology, Lipopolysaccharides pharmacology, Lymphocyte Activation, Macaca mulatta immunology, Macrophages drug effects, Macrophages pathology, Macrophages virology, Primary Cell Culture, Receptors, CCR5 genetics, Receptors, CCR5 immunology, Signal Transduction, Simian Acquired Immunodeficiency Syndrome immunology, Simian Acquired Immunodeficiency Syndrome pathology, Simian Immunodeficiency Virus metabolism, Transcription Factors genetics, Transcription Factors immunology, Viral Load, Cercocebus atys virology, Macaca mulatta virology, Macrophages immunology, Simian Acquired Immunodeficiency Syndrome virology, Simian Immunodeficiency Virus genetics, Virus Replication genetics
- Abstract
Unlabelled: Macrophages are target cells of HIV/SIV infection that may play a role in AIDS pathogenesis and contribute to the long-lived reservoir of latently infected cells during antiretroviral therapy (ART). In previous work, we and others have shown that during pathogenic SIV infection of rhesus macaques (RMs), rapid disease progression is associated with high levels of in vivo macrophage infection. In contrast, during nonpathogenic SIV infection of sooty mangabeys (SMs), neither spontaneous nor experimental CD4(+) T cell depletion results in substantial levels of in vivo macrophage infection. To test the hypothesis that SM macrophages are intrinsically more resistant to SIV infection than RM macrophages, we undertook an in vitro comparative assessment of monocyte-derived macrophages (MDMs) from both nonhuman primate species. Using the primary isolate SIVM949, which replicates well in lymphocytes from both RMs and SMs, we found that infection of RM macrophages resulted in persistent SIV-RNA production while SIV-RNA levels in SM macrophage cultures decreased 10- to 100-fold over a similar temporal course of in vitro infection. To explore potential mechanisms responsible for the lower levels of SIV replication and/or production in macrophages from SMs we comparatively assessed, in the two studied species, the expression of the SIV coreceptor as well as the expression of a number of host restriction factors. While previous studies showed that SM monocytes express lower levels of CCR5 (but not CD4) than RM monocytes, the level of CCR5 expression in MDMs was similar in the two species. Interestingly, we found that SM macrophages exhibited a significantly greater increase in the expression of tetherin (P = 0.003) and TRIM22 (P = 0.0006) in response to alpha interferon stimulation and increased expression of multiple host restriction factors in response to lipopolysaccharide stimulation and exposure to SIV. Overall, these findings confirm, in an in vitro infection system, that SM macrophages are relatively more resistant to SIV infection compared to RM macrophages, and suggest that a combination of entry and postentry restriction mechanisms may protect these cells from productive SIV infection., Importance: This manuscript represents the first in vivo comparative analysis of monocyte-derived macrophages (MDMs) between rhesus macaques, i.e., experimental SIV hosts in which the infection is pathogenic and macrophages can be infected, and sooty mangabeys, i.e., natural SIV hosts in which the infection is nonpathogenic and macrophages are virtually never infected in vivo. This study demonstrates that mangabey-derived MDMs are more resistant to SIV infection in vitro compared to macaque-derived MDMs, and provides a potential explanation for this observation by showing increased expression of specific retrovirus restriction factors in mangabey-derived macrophages. Overall, this study is important as it contributes to our understanding of why SIV infection is nonpathogenic in sooty mangabeys while it is pathogenic in macaques, and is consistent with a pathogenic role for in vivo macrophage infection during pathogenic lentiviral infection., (Copyright © 2015, American Society for Microbiology. All Rights Reserved.)
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.